CompletedPhase 1NCT03947970

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

Studying Complication in hemodialysis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cara Therapeutics, Inc.
Principal Investigator
Frédérique Menzaghi, PhD
Cara Therapeutics
Intervention
[14C] CR845(drug)
Enrollment
12 enrolled
Eligibility
18 years · MALE
Timeline
20192019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03947970 on ClinicalTrials.gov

Other trials for Complication in hemodialysis

Additional recruiting or active studies for the same condition.

See all trials for Complication in hemodialysis

← Back to all trials